myEPITOPE
Immunogenicity screening - High-precision immunogenicity prediction
myEPITOPE is myNEO's immunogenicity screening service, built on the neoIM algorithm. It estimates whether a peptide will elicit a T-cell response. It works in MHC class I and class II contexts, supporting higher immunogenicity for vaccines and lower immunogenicity for biologics.
What myEPITOPE delivers
Immunogenicity screening with myEPITOPE has a turnaround time of one week:
- Presentation prediction: identification of target epitopes likely to be presented at the cell surface across various patient populations
- Immunogenicity hotspot identification: identification of high-impact immunogenic epitope clusters across the target sequence
- Similarity-to-self analysis: isolation of the target epitopes least related to the canonical human proteome
- Coverage estimation: fine-grained predictions of target population coverage for a select set of immunogenic epitopes
- Retrospective trial analyses: increased the share of selected epitopes producing a detectable CD8+ T-cell response from 47% to 70% in a melanoma trial and from 57% to 72% in a pancreatic cancer trial
- myCONSTRUCT: next-generation string-of-beads design (optional)
- myRNA: next-generation codon optimization (optional)
What is myEPITOPE?
myEPITOPE is myNEO's immunogenicity screening service, built on the neoIM algorithm. It estimates whether a peptide will elicit a T-cell response. It works in MHC class I and class II contexts, supporting higher immunogenicity for vaccines and lower immunogenicity for biologics.
How much does myEPITOPE improve epitope selection?
In retrospective analyses of two published Phase I personalized cancer vaccine trials, myEPITOPE increased the share of selected epitopes producing a detectable CD8+ T-cell response from 47% to 70% in a melanoma trial and from 57% to 72% in a pancreatic cancer trial.
What is the turnaround time for myEPITOPE?
Immunogenicity screening with myEPITOPE has a turnaround time of one week.